• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by ReShape Lifesciences Inc. (Amendment)

    2/14/22 6:15:29 AM ET
    $RSLS
    Medical/Dental Instruments
    Health Care
    Get the next $RSLS alert in real time by email
    SC 13G/A 1 d240263dsc13ga.htm SC 13G/A SC 13G/A
    OMB APPROVAL

    OMB Number:                                          3235-0145

    Expires:                                         February 28, 2010

    Estimated average burden hours per response    10.4

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

     

    SCHEDULE 13G

    Under the Securities Exchange Act of 1934

    (AMENDMENT NO.         7            )*

     

     

    Reshape LifeSciences, Inc.

    (Name of Issuer)

    Common Stock

    (Title of Class of Securities)

    76090R101

    (CUSIP Number)

    December 31, 2021

    (Date of Event which Requires Filing of this Statement)

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☐ Rule 13d-1(b)

    ☐ Rule 13d-1(c)

    ☒ Rule 13d-1(d)

     

    *

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     


    Cusip No.

       76090R101    13G      Page 2 of 9 Pages  

     

      1    

      NAME OF REPORTING PERSONS

     

      InterWest Partners X, LP (“IWP X”)

      2  

      CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     

      (a)  ☐        (b)  ☐

      3  

      SEC USE ONLY

     

      4  

      CITIZENSHIP OR PLACE OF ORGANIZATION

     

      California

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    REPORTING

    PERSON

    WITH

       5    

      SOLE VOTING POWER

     

      6,250

       6  

      SHARED VOTING POWER

     

      0

       7  

      SOLE DISPOSITIVE POWER

     

      6,250

       8  

      SHARED DISPOSITIVE POWER

     

      0

      9    

      AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

      6,250 (1)

    10  

      CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES:

     

      ☐

    11  

      PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

      0% (2)

    12  

      TYPE OF REPORTING PERSON

     

      PN

     

    (1)

    The shares are owned by IWP X and include 6,250 shares of Common Stock issuable pursuant to common stock purchase warrants.

    (2)

    Based upon 17,784,027 shares of the Issuer’s Common Stock outstanding as of November 10, 2021, as reported in the Issuer’s Form 10-Q filed with the Securities and Exchange Commission (the “SEC”) on November 12, 2021.


    Cusip No.

       76090R101    13G      Page 3 of 9 Pages  

     

      1    

      NAME OF REPORTING PERSONS

     

      InterWest Management Partners X, LLC (the General Partner of InterWest Partners X, LP)

      2  

      CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     

      (a)  ☐        (b)  ☐

      3  

      SEC USE ONLY

     

      4  

      CITIZENSHIP OR PLACE OF ORGANIZATION

     

      California

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    REPORTING

    PERSON

    WITH

       5    

      SOLE VOTING POWER

     

      6,250

       6  

      SHARED VOTING POWER

     

      0

       7  

      SOLE DISPOSITIVE POWER

     

      6,250

       8  

      SHARED DISPOSITIVE POWER

     

      0

      9    

      AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

      6,250 (1)

    10  

      CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES:

     

      ☐

    11  

      PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

      0% (2)

    12  

      TYPE OF REPORTING PERSON

     

      OO

     

    (1)

    The shares are owned by IWP X and include 6,250 shares of Common Stock issuable pursuant to common stock purchase warrants.

    (2)

    Based upon 17,784,027 shares of the Issuer’s Common Stock outstanding as of November 10, 2021, as reported in the Issuer’s Form 10-Q filed with the Securities and Exchange Commission (the “SEC”) on November 12, 2021.


    Cusip No.

       76090R101    13G      Page 4 of 9 Pages  

     

      1    

      NAME OF REPORTING PERSONS

     

      Keval Desai (a Venture Member of InterWest Management Partners X, LLC)

      2  

      CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     

      (a)  ☐        (b)  ☐

      3  

      SEC USE ONLY

     

      4  

      CITIZENSHIP OR PLACE OF ORGANIZATION

     

      United States

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    REPORTING

    PERSON

    WITH

       5    

      SOLE VOTING POWER

     

      0

       6  

      SHARED VOTING POWER

     

      6,250

       7  

      SOLE DISPOSITIVE POWER

     

      0

       8  

      SHARED DISPOSITIVE POWER

     

      6,250

      9    

      AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

      6,250

    10  

      CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES:

     

      ☐

    11  

      PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

      0%

    12  

      TYPE OF REPORTING PERSON

     

      IN

    Neither the filing of this statement on Schedule 13G nor any of its contents shall be deemed to constitute an admission by Keval Desai that he is the beneficial owner of any of the Common Stock referred to herein for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, or for any other purpose.


    Cusip No.

       76090R101    13G      Page 5 of 9 Pages  

     

      1    

      NAME OF REPORTING PERSONS

     

      Gilbert H. Kliman (a Managing Director of InterWest Management Partners X, LLC)

      2  

      CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     

      (a)  ☐        (b)  ☐

      3  

      SEC USE ONLY

     

      4  

      CITIZENSHIP OR PLACE OF ORGANIZATION

     

      United States

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    REPORTING

    PERSON

    WITH

       5    

      SOLE VOTING POWER

     

      0

       6  

      SHARED VOTING POWER

     

      6,250

       7  

      SOLE DISPOSITIVE POWER

     

      0

       8  

      SHARED DISPOSITIVE POWER

     

      6,250

      9    

      AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

      6,250

    10  

      CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES:

     

      ☐

    11  

      PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

      0%

    12  

      TYPE OF REPORTING PERSON

     

      IN

    Neither the filing of this statement on Schedule 13G nor any of its contents shall be deemed to constitute an admission by Gilbert H. Kliman that he is the beneficial owner of any of the Common Stock referred to herein for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, or for any other purpose.


    Cusip No.

       76090R101    13G      Page 6 of 9 Pages  

     

      1    

      NAME OF REPORTING PERSONS

     

      Khaled A. Nasr (a Venture Member of InterWest Management Partners X, LLC)

      2  

      CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     

      (a)  ☐        (b)  ☐

      3  

      SEC USE ONLY

     

      4  

      CITIZENSHIP OR PLACE OF ORGANIZATION

     

      United States

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    REPORTING

    PERSON

    WITH

       5    

      SOLE VOTING POWER

     

      0

       6  

      SHARED VOTING POWER

     

      6,250

       7  

      SOLE DISPOSITIVE POWER

     

      0

       8  

      SHARED DISPOSITIVE POWER

     

      6,250

      9    

      AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

      6,250

    10  

      CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES:

     

      ☐

    11  

      PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

      0%

    12  

      TYPE OF REPORTING PERSON

     

      IN

    Neither the filing of this statement on Schedule 13G nor any of its contents shall be deemed to constitute an admission by Khaled A. Nasr that he is the beneficial owner of any of the Common Stock referred to herein for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, or for any other purpose.

     


    Cusip No.

       76090R101    13G    Page 7 of 9 Pages

     

    ITEM 1.

     

    (a)

    NAME OF ISSUER : Reshape LifeSciences, Inc.

     

    (b)

    ADDRESS OF ISSUER’S PRINCIPAL EXECUTIVE OFFICE:

    1001 Calle Amanecer, San Clemente, CA 92673

     

    ITEM 2.

     

    (a)

    NAME OF PERSON(S) FILING:

    InterWest Partners X, LP (“IWP X”)

    InterWest Management Partners X, LLC (“IMP X”)

    Keval Desai (“Desai”)

    Gilbert H. Kliman (“Kliman”)

    Khaled A. Nasr (“Nasr”)

     

    (b)

    ADDRESS OF PRINCIPAL BUSINESS OFFICE OR, IF NONE, RESIDENCE:

    467 First Street, Suite 201, Los Altos, CA 94022

     

    (c)

    CITIZENSHIP/PLACE OF ORGANIZATION:

    IWP X:             California

    IMP X:             California

    Desai:               United States

    Kliman:            United States

    Nasr:                United States

     

    (d)

    TITLE OF CLASS OF SECURITIES: Common Stock

     

    (e)

    CUSIP NUMBER: 76090R101

    ITEM 3. NOT APPLICABLE.

     


    Cusip No.

       76090R101    13G    Page 8 of 9 Pages

     

    ITEM 4.

    OWNERSHIP.

     

          IWP X     IMP X (1)     Desai (2)  

    Beneficial Ownership

         6,250  (3)      6,250  (3)      6,250  (3) 

    Percentage of Class

         0 % (4)      0 % (4)      0 % (4) 

    Sole Voting Power

         6,250       6,250       0  

    Shared Voting Power

         0       0       6,250  

    Sole Dispositive Power

         6,250       6,250       0  

    Shared Dispositive Power

         0       0       6,250  

     

          Kliman (2)     Nasr (2)  

    Beneficial Ownership

         6,250  (3)      6,250  (3) 

    Percentage of Class

         0 % (4)      0 % (4) 

    Sole Voting Power

         0       0  

    Shared Voting Power

         6,250       6,250  

    Sole Dispositive Power

         0       0  

    Shared Dispositive Power

         6,250       6,250  

     

      (1)

    IMP X is the general partner of IWP X.

      (2)

    Kliman is a Managing Director of IMP X. Desai and Nasr are Venture Members of IMP X. The Managing Directors and Venture Members of IMP X share voting and investment control over shares held by IWP X.

      (3)

    The shares are owned by IWP X and include 6,250 shares of Common Stock issuable pursuant to common stock purchase warrants.

      (4)

    Based upon 17,784,027 shares of the Issuer’s Common Stock outstanding as of November 10, 2021, as reported in the Issuer’s Form 10-Q filed with the Securities and Exchange Commission (the “SEC”) on November 12, 2021.

    ITEM 5. OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS.

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following ☒

    ITEM 6. OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON.

    Under certain circumstances set forth in the limited liability company operating agreement of IMP X, the members of such limited liability company have the right to receive dividends from, or the proceeds from the sale of, the common stock of Issuer beneficially owned by such limited liability company.

    ITEM 7. IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY.

    Not applicable.

    ITEM 8. IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP.

    No reporting person is a member of a group as defined in section 240.13d-1(b)(1)(iii)(H) of the Act.

    ITEM 9. NOTICE OF DISSOLUTION OF THE GROUP.

    Not applicable.

     


    Cusip No.

       76090R101    13G    Page 9 of 9 Pages

     

    ITEM 10.

    CERTIFICATION.

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

    EXHIBITS

    Joint Filing Statement attached as Exhibit A.

    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Date: February 14, 2022
    INTERWEST PARTNERS X, LP
    By:   InterWest Management Partners X, LLC, its General Partner
    By:   /s/Gilbert H. Kliman by Karen A. Wilson, Power of Attorney
      Managing Director
    INTERWEST MANAGEMENT PARTNERS X, LLC
    By:   /s/Gilbert H. Kliman by Karen A. Wilson, Power of Attorney
      Managing Director
    By:   /s/ Keval Desai by Karen A. Wilson, Power of Attorney
    Name:   Keval Desai
    By:   /s/Gilbert H. Kliman by Karen A. Wilson, Power of Attorney
    Name:   Gilbert H. Kliman
    By:   /s/ Khaled A. Nasr
    Name:   Khaled A. Nasr
    Get the next $RSLS alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $RSLS

    DatePrice TargetRatingAnalyst
    10/8/2021$8.00Buy
    Maxim Group
    More analyst ratings

    $RSLS
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • ReShape Lifesciences® Reports First Quarter Ended March 31, 2025 Financial Results and Provides Corporate Update

      IRVINE, Calif., May 21, 2025 (GLOBE NEWSWIRE) -- ReShape Lifesciences Inc. (NASDAQ:RSLS), the premier physician-led weight loss and metabolic health-solutions company, today reported financial results for the first quarter ended March 31, 2025 and provided a corporate strategic update. First Quarter 2025 and Subsequent Highlights May 2025: Effected a 1-for-25 reverse stock split of the company's common stock, which was effective for trading purposes upon the commencement of trading on May 9, 2025.May 2025: Presented pre-clinical data on its proprietary Diabetes Neuromodulation device in a poster presentation at the 12th Annual Minnesota Neuromodulation Symposium.

      5/21/25 8:31:00 AM ET
      $RSLS
      Medical/Dental Instruments
      Health Care
    • ReShape Lifesciences Announces 1-for-25 Reverse Stock Split

      IRVINE, Calif., May 07, 2025 (GLOBE NEWSWIRE) -- ReShape Lifesciences Inc. (NASDAQ:RSLS), the premier physician-led weight loss and metabolic health solutions company, today announced that its Board of Directors has declared a 1-for-25 reverse stock split of the company's common stock, which will be effective for trading purposes upon the commencement of trading on May 9, 2025. At that time, each 25 shares of issued and outstanding common stock and equivalents will be converted into one share of common stock. As a result of the reverse stock split, proportional adjustments will be made to the number of shares of common stock issuable upon exercise or conversion, and the per share exercise

      5/7/25 8:31:00 AM ET
      $RSLS
      Medical/Dental Instruments
      Health Care
    • ReShape Lifesciences® Presents Pre-clinical Data on Its Proprietary Diabetes Neuromodulation Device at the 12th Annual Minnesota Neuromodulation Symposium

      Vagal Neuromodulation Offers a Novel Approach to Treating Diabetes and Hypoglycemia Device Demonstrates the Ability to Modulate Glucose Levels Without Cardiac Side Effects, Overcoming a Key Limitation Of Conventional Vagal Stimulation Techniques IRVINE, Calif., May 02, 2025 (GLOBE NEWSWIRE) -- ReShape Lifesciences® (NASDAQ:RSLS), the premier physician-led weight loss and metabolic health solutions company, today announced it will present pre-clinical data on its proprietary Diabetes Neuromodulation device in a poster presentation at the 12th Annual Minnesota Neuromodulation Symposium, being held in Minneapolis. Poster Presentation Details: Poster Title: Stimulation of the Posterior Sub

      5/2/25 8:31:00 AM ET
      $RSLS
      Medical/Dental Instruments
      Health Care

    $RSLS
    SEC Filings

    See more
    • SEC Form 10-Q filed by ReShape Lifesciences Inc.

      10-Q - ReShape Lifesciences Inc. (0001427570) (Filer)

      5/20/25 4:56:06 PM ET
      $RSLS
      Medical/Dental Instruments
      Health Care
    • SEC Form NT 10-Q filed by ReShape Lifesciences Inc.

      NT 10-Q - ReShape Lifesciences Inc. (0001427570) (Filer)

      5/15/25 4:06:10 PM ET
      $RSLS
      Medical/Dental Instruments
      Health Care
    • SEC Form EFFECT filed by ReShape Lifesciences Inc.

      EFFECT - ReShape Lifesciences Inc. (0001427570) (Filer)

      5/15/25 12:15:15 AM ET
      $RSLS
      Medical/Dental Instruments
      Health Care

    $RSLS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Financial Officer Stankovich Thomas sold $39 worth of shares (172 units at $0.23), decreasing direct ownership by 0.75% to 22,777 units (SEC Form 4)

      4 - ReShape Lifesciences Inc. (0001427570) (Issuer)

      8/13/24 4:29:13 PM ET
      $RSLS
      Medical/Dental Instruments
      Health Care
    • New insider Schneid Yair claimed ownership of 2,461,000 shares (SEC Form 3)

      3 - ReShape Lifesciences Inc. (0001427570) (Issuer)

      1/16/24 6:11:06 PM ET
      $RSLS
      Medical/Dental Instruments
      Health Care
    • Stankovich Thomas sold $386 worth of shares (435 units at $0.89), decreasing direct ownership by 2% to 22,949 units (SEC Form 4)

      4 - ReShape Lifesciences Inc. (0001427570) (Issuer)

      11/8/23 4:16:25 PM ET
      $RSLS
      Medical/Dental Instruments
      Health Care

    $RSLS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Maxim Group initiated coverage on Reshape Lifesciences with a new price target

      Maxim Group initiated coverage of Reshape Lifesciences with a rating of Buy and set a new price target of $8.00

      10/8/21 9:13:24 AM ET
      $RSLS
      Medical/Dental Instruments
      Health Care

    $RSLS
    Leadership Updates

    Live Leadership Updates

    See more
    • ReShape Lifesciences Appoints Seasoned Sales and Marketing Executive, Nick Ansari, as Senior Vice President of Global Commercial Operations

      SAN CLEMENTE, Calif., Aug. 23, 2022 (GLOBE NEWSWIRE) -- ReShape Lifesciences™ (NASDAQ:RSLS), the premier physician-led weight loss and metabolic health solutions company, today announced that the company has appointed Nick Ansari as Senior Vice President of Global Commercial Operations, effective September 6, 2022. Mr. Ansari, who, from 2014 to 2019 was Senior Vice President Global Sales for Enteromedics, the predecessor company to Reshape, will be responsible for strengthening the executional efficiencies of the sales and marketing team, worldwide. In this role, he will report directly to Mr. Paul F. Hickey, ReShape's President and Chief Executive Officer. "Nick is a proven executive

      8/23/22 8:30:00 AM ET
      $RSLS
      Medical/Dental Instruments
      Health Care
    • ReShape Lifesciences Announces Appointment of Paul F. Hickey as President and Chief Executive Officer

      SAN CLEMENTE, Calif., July 27, 2022 (GLOBE NEWSWIRE) -- ReShape Lifesciences™ (NASDAQ:RSLS), the premier physician-led weight loss and metabolic health solutions company, today announced that its Board of Directors has appointed Paul F. Hickey as President and Chief Executive Officer and as a member of the Board of Directors, effective August 15, 2022. Mr. Hickey succeeds Bart Bandy, who has separated from the company to pursue other opportunities. Thomas Stankovich, Chief Financial Officer of ReShape, will serve as Interim President and Chief Executive Officer until Mr. Hickey joins the company. Dan W. Gladney, current Chair of the Board of Directors, will assume a more active role as Exe

      7/27/22 4:05:00 PM ET
      $RSLS
      Medical/Dental Instruments
      Health Care
    • ReShape Lifesciences Strengthens Leadership Team with Appointment of Michael Bordainick as Senior Vice President, Commercial Operations

      SAN CLEMENTE, Calif., Jan. 13, 2022 (GLOBE NEWSWIRE) -- ReShape Lifesciences Inc. (NASDAQ:RSLS), the premier physician-led weight loss and metabolic health-solutions company, today announced the appointment of Michael Bordainick as its Senior Vice President, Commercial Operations. In this newly created role, as part of the Company's next phase of operational growth, Mr. Bordainick will be responsible for strengthening the strategic development and executional efficiencies of the sales and marketing teams. "As Michael brings significant experience and capabilities to advance ReShape's recently launched commercial programs, including direct-to-consumer marketing and enhanced support for o

      1/13/22 8:30:00 AM ET
      $RSLS
      Medical/Dental Instruments
      Health Care

    $RSLS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by ReShape Lifesciences Inc.

      SC 13G/A - ReShape Lifesciences Inc. (0001427570) (Subject)

      9/26/24 4:45:20 PM ET
      $RSLS
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13D filed by ReShape Lifesciences Inc.

      SC 13D - ReShape Lifesciences Inc. (0001427570) (Subject)

      3/17/23 5:01:18 PM ET
      $RSLS
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13D filed by ReShape Lifesciences Inc.

      SC 13D - ReShape Lifesciences Inc. (0001427570) (Subject)

      2/15/23 3:34:19 PM ET
      $RSLS
      Medical/Dental Instruments
      Health Care

    $RSLS
    Financials

    Live finance-specific insights

    See more
    • ReShape Lifesciences® to Announce Financial Results for the Third Quarter Ended September 30, 2024, and Provide Corporate Update

      IRVINE, Calif., Nov. 12, 2024 (GLOBE NEWSWIRE) -- ReShape Lifesciences Inc. (NASDAQ:RSLS), the premier physician-led weight loss and metabolic health-solutions company, today announced that it will report its financial results for the third quarter ended September 30, 2024, including a corporate update on Thursday, November 14, 2024, after market. Management will host a conference call on Thursday, November 14 at 4:30 pm ET, and will be joined by Krishna K. Gupta, a current Director of Vyome Therapeutics, who will be appointed Chairman of the combined company upon completion of the previously announced merger agreement between the two companies. A live webcast will be available on the

      11/12/24 4:05:00 PM ET
      $RSLS
      Medical/Dental Instruments
      Health Care
    • ReShape Lifesciences® to Announce Financial Results for the Second Quarter Ended June 30, 2024, and Provide Corporate Update

      IRVINE, Calif., Aug. 13, 2024 (GLOBE NEWSWIRE) -- ReShape Lifesciences Inc. (NASDAQ:RSLS), the premier physician-led weight loss and metabolic health-solutions company, today announced that it will report its financial results for the second quarter ended June 30, 2024, including a corporate update on Wednesday, August 14, 2024, after market. Management will host a conference call on August 15 at 4:30 pm ET, and will be joined by Krishna K. Gupta, a current Director of Vyome Therapeutics, who will be appointed Chairman of the combined company upon completion of the previously announced merger agreement between the two companies. A live webcast will be available on the "Events and Presenta

      8/13/24 8:31:00 AM ET
      $RSLS
      Medical/Dental Instruments
      Health Care
    • ReShape Lifesciences® Reports First Quarter Ended March 31, 2024 Financial Results and Provides Corporate Update

      Commercial Launch of Next-Generation Lap-Band® 2.0 FLEX Continues Significant Reduction in Overall Operating Expenses of 51% in the First Quarter of 2024 Compared to the First Quarter of 2023 Implementation of 2024 Cost Reduction Plan Continues, Expected to Reduce Operating Expenses by 55.4% Compared to 2023 Conference Call to be Held at 4:30 pm ET Today IRVINE, Calif., May 15, 2024 (GLOBE NEWSWIRE) -- ReShape Lifesciences Inc. (NASDAQ:RSLS), the premier physician-led weight loss and metabolic health-solutions company, today reported financial results for the first quarter ended March 31, 2024 and provided a corporate strategic update. First Quarter 2024 and Subsequent Highlights Ma

      5/15/24 4:05:00 PM ET
      $RSLS
      Medical/Dental Instruments
      Health Care